Implicit to develop ex-Icos antibody for lung injury
This article was originally published in Scrip
Implicit Bioscience has acquired from Lilly a CD14-targeting antibody, which it will develop as a treatment for acute lung injury (ALI). The US major has received an undisclosed cash payment and has also taken an equity stake in the private Australian firm, which will pay royalties on future sales of the therapy.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context